This page is part of the FHIR Specification (v3.5.0: R4 Ballot #2). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R5R4BR4
RXD-20-Substance Manufacturer Name / RXG-21-Substance Manufacturer Name / RXA-17-Substance Manufacturer Name
doseForm
RXO-5-Requested Dosage Form / RXE-6-Give Dosage Form / RXD-6-Actual Dosage Form / RXG-8-Give Dosage Form / RXA-8-Administered Dosage Form
amount
synonym
relatedMedicationKnowledge
type
reference
associatedMedication
productType
monograph
type
source
ingredient
item[x]
RXC-2-Component Code if medication: RXO-1-Requested Give Code / RXE-2-Give Code / RXD-2-Dispense/Give Code / RXG-4-Give Code / RXA-5-Administered Code
isActive
strength
RXC-3-Component Amount & RXC-4-Component Units if medication: RXO-2-Requested Give Amount - Minimum & RXO-4-Requested Give Units / RXO-3-Requested Give Amount - Maximum & RXO-4-Requested Give Units / RXO-11-Requested Dispense Amount & RXO-12-Requested Dispense Units / RXE-3-Give Amount - Minimum & RXE-5-Give Units / RXE-4-Give Amount - Maximum & RXE-5-Give Units / RXE-10-Dispense Amount & RXE-10-Dispense Units
preparationInstruction
intendedRoute
cost
type
source
cost
monitoringProgram
type
name
administrationGuidelines
dosage
type
dosage
indication[x]
patientCharacteristics
characteristic[x]
value
medicineClassification
type
classification
packaging
type
quantity
drugCharacteristic
type
value[x]
contraindication
regulatory
regulatoryAuthority
substitution
type
allowed
schedule
schedule
maxDispense
quantity
period
kinetics
areaUnderCurve
lethalDose50
halfLifePeriod
11.6.6.3 Mappings for RIM Mapping (http://hl7.org/v3)